Walleye Capital
BIB icon

Walleye Capital’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Walleye Capital’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,433
Closed -$275K – 2366
2022
Q1 		$275K Buy
+4,433
New +$272K 0.01% 1354

Other funds holding BIB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
MCC
Money Concepts Capital Palm Beach Gardens, Florida $1.81B AUM 21.93% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Walleye Capital's BIB Position: Q2 2022 in Review

Walleye Capital sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2022, closing a stake of 4,433 shares — an estimated $275K sold.

Walleye Capital first reported a position in BIB in Q1 2022 and held it in 1 quarter. The position peaked at $275K in Q1 2022. 24 funds tracked by Wall St. Rank hold BIB as of Q2 2022.

  • Walleye Capital reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2022 after selling out during the quarter.
  • Walleye Capital sold 4,433 ProShares Ultra NASDAQ Biotechnology shares in Q2 2022, an estimated $275K.
  • Walleye Capital first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2022 and held it in 1 quarter.
  • Walleye Capital's ProShares Ultra NASDAQ Biotechnology position peaked at $275K in Q1 2022.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.